{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Saline+0.9%25&page=27",
    "query": {
      "intervention": "Saline 0.9%",
      "page": 27
    },
    "page_size": 10
  },
  "pagination": {
    "page": 27,
    "page_size": 10,
    "total_count": 1514,
    "total_pages": 152,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Saline+0.9%25&page=28&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Saline+0.9%25&page=26&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-23T07:37:29.133Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00606502",
      "title": "Study of Pralatrexate vs. Erlotinib for Non-Small Cell Lung Cancer After at Least 1 Prior Platinum-based Treatment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Pralatrexate",
          "type": "DRUG"
        },
        {
          "name": "Erlotinib",
          "type": "DRUG"
        },
        {
          "name": "Vitamin B12",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Folic Acid",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Spectrum Pharmaceuticals, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 201,
      "start_date": "2008-01",
      "completion_date": "2010-06-24",
      "has_results": true,
      "last_update_posted_date": "2021-03-05",
      "last_synced_at": "2026-10-23T07:37:29.133Z",
      "location_count": 15,
      "location_summary": "Bakersfield, California • San Diego, California • Port Saint Lucie, Florida + 12 more",
      "locations": [
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Port Saint Lucie",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Westwood",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00606502"
    },
    {
      "nct_id": "NCT02760407",
      "title": "Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "Olokizumab 64mg q4w",
          "type": "DRUG"
        },
        {
          "name": "Olokizumab 64mg q2w",
          "type": "DRUG"
        },
        {
          "name": "Adalimumab 40mg q2w",
          "type": "DRUG"
        },
        {
          "name": "Placebo q2w",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "R-Pharm International, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1648,
      "start_date": "2016-06-06",
      "completion_date": "2019-11-05",
      "has_results": true,
      "last_update_posted_date": "2023-09-21",
      "last_synced_at": "2026-10-23T07:37:29.133Z",
      "location_count": 64,
      "location_summary": "Mesa, Arizona • Phoenix, Arizona • Sun City, Arizona + 55 more",
      "locations": [
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Covina",
          "state": "California"
        },
        {
          "city": "El Cajon",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02760407"
    },
    {
      "nct_id": "NCT02227329",
      "title": "Prophylactic Ethanol Lock Therapy (ELT) in Patients on Home Parenteral Nutrition",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Catheter-related Bloodstream Infection (CRBSI) Nos",
        "Bloodstream Infection Due to Central Venous Catheter",
        "Bloodstream Infection Due to Hickman Catheter"
      ],
      "interventions": [
        {
          "name": "Ethanol",
          "type": "DRUG"
        },
        {
          "name": "Heparin Lock",
          "type": "DRUG"
        },
        {
          "name": "Normal Saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 39,
      "start_date": "2014-07",
      "completion_date": "2016-10",
      "has_results": true,
      "last_update_posted_date": "2017-12-12",
      "last_synced_at": "2026-10-23T07:37:29.133Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02227329"
    },
    {
      "nct_id": "NCT06597019",
      "title": "Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Familial Hypercholesterolemia - Heterozygous"
      ],
      "interventions": [
        {
          "name": "Inclisiran",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "11 Years",
        "sex": "ALL",
        "summary": "6 Years to 11 Years"
      },
      "enrollment_count": 60,
      "start_date": "2024-12-09",
      "completion_date": "2029-04-15",
      "has_results": false,
      "last_update_posted_date": "2026-05-15",
      "last_synced_at": "2026-10-23T07:37:29.133Z",
      "location_count": 9,
      "location_summary": "San Francisco, California • Washington D.C., District of Columbia • Boca Raton, Florida + 4 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Boca Raton",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06597019"
    },
    {
      "nct_id": "NCT03219983",
      "title": "Pain Management After Total Shoulder Arthroplasty",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Glenohumeral Arthritis",
        "Total Shoulder Arthroplasty"
      ],
      "interventions": [
        {
          "name": "Ropivacaine",
          "type": "DRUG"
        },
        {
          "name": "liposomal bupivacaine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The Christ Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 22,
      "start_date": "2016-11",
      "completion_date": "2017-09",
      "has_results": false,
      "last_update_posted_date": "2017-11-06",
      "last_synced_at": "2026-10-23T07:37:29.133Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03219983"
    },
    {
      "nct_id": "NCT02505542",
      "title": "Study to Evaluate Maintenance of Sustained Remission of axSpA With CZP Compared to Placebo",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Axial Spondyloarthrithis",
        "Ankylosing Spondylitis"
      ],
      "interventions": [
        {
          "name": "Certolizumab Pegol",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "UCB BIOSCIENCES GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 736,
      "start_date": "2015-07",
      "completion_date": "2019-04",
      "has_results": true,
      "last_update_posted_date": "2020-12-17",
      "last_synced_at": "2026-10-23T07:37:29.133Z",
      "location_count": 16,
      "location_summary": "Glendale, Arizona • Mesa, Arizona • Phoenix, Arizona + 13 more",
      "locations": [
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Palm Desert",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02505542"
    },
    {
      "nct_id": "NCT00423722",
      "title": "Parenteral Hydration in Advanced Cancer Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Advanced Cancer",
        "Dehydration"
      ],
      "interventions": [
        {
          "name": "Saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 262,
      "start_date": "2007-01-09",
      "completion_date": "2013-05",
      "has_results": true,
      "last_update_posted_date": "2024-03-12",
      "last_synced_at": "2026-10-23T07:37:29.133Z",
      "location_count": 5,
      "location_summary": "Conroe, Texas • Houston, Texas",
      "locations": [
        {
          "city": "Conroe",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00423722"
    },
    {
      "nct_id": "NCT04199754",
      "title": "IV Contrast-Enhanced Cone Beam Computed Tomography (CBCT) in Radiotherapy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Pelvic Cancer",
        "Abdominal Cancer"
      ],
      "interventions": [
        {
          "name": "Omnipaque 300mg/mL Solution for Injection",
          "type": "DRUG"
        },
        {
          "name": "Cone Beam CT",
          "type": "RADIATION"
        },
        {
          "name": "Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "0.9% Saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Columbia University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2020-10-01",
      "completion_date": "2021-05-28",
      "has_results": false,
      "last_update_posted_date": "2024-05-31",
      "last_synced_at": "2026-10-23T07:37:29.133Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04199754"
    },
    {
      "nct_id": "NCT01303705",
      "title": "Anti-OX40, Cyclophosphamide (CTX) and Radiation in Patients With Progressive Metastatic Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Prostate Cancer",
        "Cancer of the Prostate",
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Anti-OX40",
          "type": "DRUG"
        },
        {
          "name": "Radiation",
          "type": "RADIATION"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Providence Health & Services",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 13,
      "start_date": "2010-10-14",
      "completion_date": "2016-07-05",
      "has_results": false,
      "last_update_posted_date": "2018-08-29",
      "last_synced_at": "2026-10-23T07:37:29.133Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01303705"
    },
    {
      "nct_id": "NCT03899883",
      "title": "Uric Acid Lowering Trial in Youth Onset T2D",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetic Kidney Disease",
        "Hyperuricemia",
        "Diabetes",
        "Diabetes Mellitus, Type 2",
        "Type2 Diabetes",
        "Type 2 Diabetes Mellitus",
        "Diabetic Nephropathies",
        "Diabetes Complications"
      ],
      "interventions": [
        {
          "name": "Pegloticase 8 MG/ML [Krystexxa]",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "25 Years",
        "sex": "MALE",
        "summary": "18 Years to 25 Years · Male only"
      },
      "enrollment_count": 11,
      "start_date": "2020-01-01",
      "completion_date": "2023-04-13",
      "has_results": true,
      "last_update_posted_date": "2026-07-28",
      "last_synced_at": "2026-10-23T07:37:29.133Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03899883"
    }
  ]
}